文献速递心力衰竭与心肌病心律失常

CXCR6+ T细胞驱动免疫检查点抑制剂心肌炎

CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis.
PubMed 文献 · Circulation · 2026-01-07

该研究利用药物警戒数据库发现抗LAG-3联合治疗增加心肌炎风险,并通过Lag3-/-Pdcd1-/-小鼠模型证实其发生严重心脏炎症、心律失常和早亡。单细胞测序等显示CXCR6是活化心脏T细胞的关键标志,抗CXCR6抗体可减轻病变,提示CXCR6+ T细胞是致病所必需且为潜在治疗靶点。

要点

  • 抗LAG-3联合抗PD-1治疗与心肌炎风险增加相关。
  • Lag3-/-Pdcd1-/-小鼠自发严重心肌炎、心律失常并于6-8周早亡。
  • 抗CXCR6抗体可预防早亡、减轻心律失常和心肌炎病理 severity。

核心结论

  • ICI心肌炎由CXCR6+ T细胞扩增驱动,CXCR6是潜在治疗靶点。

研究设计与样本

  • 利用VigiBase药物警戒数据库评估抗LAG-3与其他ICI方案的心肌炎风险。
  • 使用Lag3-/-Pdcd1-/-小鼠模型,通过组织学、流式细胞术、心电图、单细胞RNA测序和抗体诱导细胞清除进行心脏表型分析。

主要发现

  • 临床上抗LAG-3联合治疗心肌炎风险增加,证实早期临床试验数据。
  • Lag3-/-Pdcd1-/-小鼠出现严重心脏炎症,伴心脏巨噬细胞和克隆性T细胞增多,并发生自发性心律失常导致6至8周早亡。
  • CXCR6标记活化的心脏T细胞,包括Gzmk、Gzmb、Cd4和活跃分裂T细胞的不同簇,其配体CXCL16在心脏巨噬细胞中上调。
  • 抗CXCR6抗体治疗预防早亡、减轻心律失常并降低心肌炎组织学严重程度。

临床怎么用

  • 抗LAG-3联合治疗时需警惕心肌炎风险。
  • CXCR6+ T细胞可作为ICI心肌炎的潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myocarditis is a severe complication of immune checkpoint inhibitors (ICIs). The major risk factor for ICI myocarditis is the use of combination ICI treatment, especially when relatlimab, a novel anti-LAG-3 (lymphocyte-activation gene 3) antibody, is combined with anti-PD-1 (programmed cell death protein 1) therapy. Although pathogenic T cells are necessary for ICI myocarditis, the specific signaling and T-cell populations that drive cardiac infiltration have not been fully elucidated, especially in setting of anti-LAG-3/PD-1 treatment. METHODS: We used VigiBase, an international pharmacovigilance database, to assess the risk of myocarditis with anti-LAG-3 compared with other ICI treatment regimens. We identified a mouse model of LAG-3/PD-1-associated ICI myocarditis through genetic deletion of immune checkpoints LAG-3 and PD-1 (Lag3-/-, Pdcd1-/- mice) and performed rigorous cardiac phenotyping using histology, flow cytometry, electrocardiography, single-cell RNA sequencing, and antibody-induced cellular depletion. RESULTS: We found an increased risk of myocarditis with anti-LAG-3 combination treatment clinically, confirming early clinical trial data. Lag3-/-, Pdcd1-/- mice were found to develop severe cardiac inflammation by histology with increased cardiac macrophages and clonal T cells, which was associated with the development of spontaneous arrhythmias leading to premature death by 6 to 8 weeks. We identified CXCR6 (C-X-C motif chemokine receptor 6) as a key marker of activated cardiac T cells in this model, along with analogous signals in other preclinical models and patient data. CXCR6 marked a heterogenous group of cardiac T cells, including distinct clusters of Gzmk, Gzmb, Cd4, and actively dividing T cells. CXCL16 (C-X-C motif chemokine ligand 16), the sole known ligand for CXCR6, was similarly upregulated in the cardiac macrophage population. Treatment with anti-CXCR6 antibody prevented premature lethality, attenuated arrhythmias, and reduced the histological severity of myocarditis, demonstrating that CXCR6+ T cells are necessary for disease pathogenesis. CONCLUSIONS: Our findings suggest that ICI myocarditis is driven by an expansion of CXCR6+ T cells and identifies CXCR6 as a putative therapeutic target for this highly morbid condition.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Munir AZ, Gutierrez A, Krawiec CJ, et al. CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis. Circulation. 2026. PMID: 41498147. doi:10.1161/CIRCULATIONAHA.125.076976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。